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In aggressive, rapidly growing solid tumors such
as glioblastoma multiforme (GBM), cancer cells
face frequent dynamic changes in their microenvi-
ronment, including the availability of glucose and
other nutrients. These challenges require that tumor
cells have the ability to adapt in order to survive pe-
riods of nutrient/energy starvation. We have identi-
fied a reciprocal negative feedback loop mechanism
in which the levels of microRNA-451 (miR-451)
are negatively regulated through the phosphorylation
and inactivation of its direct transcriptional activator
OCT1 by 50 AMP-activated protein kinase (AMPK),
which is activated by glucose depletion-induced
metabolic stress. Conversely, in a glucose-rich envi-
ronment, unrestrained expression of miR-451 sup-
presses AMPK pathway activity. These findings
uncover miR-451 as a major effector of glucose-
regulated AMPK signaling, allowing tumor cell
adaptation to variations in nutrient availability in the
tumor microenvironment.INTRODUCTION
Glioblastoma multiforme (GBM) is one of the most lethal can-
cers, with a median survival of 14.6 months with the current
standard of care (Stupp et al., 2005). GBM displays a high prolif-
erative index sustained by modifications in blood supply that
results in dynamic microenvironmental fluctuations in the avail-
ability of oxygen, glucose, and other nutrients. This requires
that tumor cells can rapidly adapt to survive periods of nutrient
starvation. GBM cells are also highly dependent on elevated
glucose uptake (Flavahan et al., 2013). Adaptation to metabolic
stress in cancer requires transient cellular alterations controlled
by changes in transcriptional activity (Dhruv et al., 2013; Ho¨ring
et al., 2012). Uncovering the molecular circuitry by which alter-902 Cell Reports 11, 902–909, May 12, 2015 ª2015 The Authorsations in glucose metabolism allow for cancer cell adaptation
may provide new insights into cancer pathogenesis (Ward and
Thompson, 2012a, 2012b).
50 AMP-activated protein kinase (AMPK) is a critical cellular
energy sensor. Inadequate energy supply results in a conforma-
tional change induced by AMP, allowing activation of AMPK by
the LKB1 complex. Once activated, AMPKpromotes cell survival
by increasing catabolic processes while conserving ATP by
switching off anabolic pathways (Hardie et al., 2012).
MicroRNAs are short, non-coding RNA molecules capable of
regulating the levels of multiple proteins via binding to specific
mRNA targets, thereby suppressing their translation, and dereg-
ulation of microRNAs has been described in multiple human
malignancies (Iorio and Croce, 2012), including GBM (Godlewski
et al., 2010b). We previously demonstrated that miR-451
expressed in GBM cells blocks migration and acts as a potent
inhibitor of AMPK signaling by targeting components of LKB1 ki-
nase complex as well as numerous downstream effectors. We
also demonstrated that miR-451 levels decrease in low glucose,
resulting in AMPK activation and increased cell migration (God-
lewski et al., 2010a, 2010c).
In this paper, we report that miR-451 transcription in GBM
cells is driven by the transcription factor OCT1 (official gene
symbol POU2F1) and that AMPK activation by glucose depri-
vation leads to inactivation of OCT1 via direct phosphorylation
at serine 335, which leads to inhibition of miR-451 transcrip-
tion. Inhibition of miR-451 in turn results in sustained AMPK
activation and a robust response to glucose deprivation in
GBM cells. Conversely, in the presence of abundant glucose,
unrestricted activity of OCT1 drives transcription of miR-451,
leading to AMPK inhibition via direct targeting of CAB39—a
component of the LKB1 complex (Godlewski et al., 2010c).
This study highlights the role of an AMPK/miR-451 reciprocal
feedback loop in the adaptation of GBM cells to metabolic
stress.
MATERIALS AND METHODS
For standard experimental procedures (cell culture, antibodies, real-time PCR,
western blotting, siRNA transfections, luciferase reporter assays, chromatin
Figure 1. Glucose Regulates the Levels of pri-miR-451
(A) qRT-PCR analysis of pri-miR-451 expression after 18 hr in low glucose. See also Figures S1A and S1B. *p < 0.05, **p < 0.01. Mean ± SD.
(B) Glucose depletion by proliferating cells (left). qRT-PCR analysis of pri-miR-451 expression in glucose-depleted media (right panels). See also Figure S1C.
*p < 0.05, **p < 0.01. Mean ± SD.
(C) Glucose regimens used in the experiment (left). qRT-PCR analysis of pri-miR-451 expression in different glucose regimens (right panels). See also Figure S1D.
*p < 0.05, **p < 0.01. Mean ± SD.immunoprecipitation [ChIP], and expression of truncated OCT1), see the Sup-
plemental Experimental Procedures.
Human Specimens and In Vivo Studies
All tumor samples were obtained as approved by the Institutional Review
Board at The Ohio State University and Brigham and Women’s Hospital
(BWH). For all studies, the mice were housed in animal facility at the BWH in
accordance with all NIH regulations. All protocols were approved by the
BWH Institutional Animal Care and Use Committee. See the Supplemental
Experimental Procedures for in vivo studies procedures.
Oct1-Deficient and AMPKb1/2-Deficient Cell Lines
3T3 Oct1/ mouse fibroblasts and T98G GBM cells stably expressing
AMPKb1/2-specific shRNA lentiviral constructs were obtained from the labo-
ratories of Drs. Dean Tantin (University of Utah) and Biplab Dasgupta (Cincin-
nati Children’s Hospital Medical Center), respectively.
Kinase Assays
WT GST-OCT1 or GST-OCT1-S3353A peptides were dialyzed overnight
using HEPES buffer (pH 7.0; 62.5 mM Na HEPES [pH 7.0]; 62.5 mM NaCl;
62.5 mM NaF; 6.25 mM Na pyrophosphate; 1.25 mM EDTA, 1.25 mM
EGTA; 1 mM DTT, 1 mM PMSF; 2 mM sodium orthovanadate, 10 mg/ml apro-
tinin; 10 mg/ml leupeptin; and 10 mg/ml pepstatin A). For kinase assays,
100 mg GST-OCT1 WT or GST-OCT1-S3353A were incubated in the presence
of 100 mg AMPK-IP or 100 ng recombinant AMPK complex containing phos-
pho-AMPKa1, AMPKb1, and AMPKg1 in the presence of 0.2 mM ATP for 1 hr
at 30C following suppliers’ instructions. The phosphorylation of OCT1 was
analyzed by western blotting using anti-phospho-OCT1 (S335; a gift fromDean Tantin, University of Utah) and OCT1. Anti-GST was used as a loading
control.
RESULTS
Glucose Regulates miR-451 Expression
To examine AMPK/miR-451 signaling in response to glucose
deprivation, we measured the levels of primary miR-451
(pri-miR-451) in a panel of GBM cells cultured in 0.3 g/l for
16–18 hr (‘‘low glucose’’ conditions), which is considered phys-
iologically relevant range (Flavahan et al., 2013). This led to a
significant decline in pri-miR-451 levels compared with high
glucose (4.5 g/l) conditions in all GBM cell lines. This was
also seen in 3T3, but not in HeLa cells with defective AMPK
signaling (Lizcano et al., 2004) (Figure 1A). When GBM cells
were cultured in high glucose without replenishment, glucose
was depleted from 4.5 g/l to less than 1.0 g/l in 72 hr, and
this was associated with a decrease in pri-miR-451 levels (Fig-
ure 1B). GBM cells were cultured in three different regimens:
continuously high glucose (medium replenished every 12 hr),
continuously low glucose, and low glucose replenished at
24 hr with a pulse of high glucose medium. In high glucose,
the expression of pri-miR-451 remained high, while in low
glucose it significantly dropped. In the third group, pri-miR-
451 increased after the glucose pulse and then levels graduallyCell Reports 11, 902–909, May 12, 2015 ª2015 The Authors 903
Figure 2. OCT1 Is a Positive Transcriptional Modulator of miR-451
(A) A schematic representation of OCT1 binding sites within the putative promoter of miR-451 and cloned fragments (C1–C5). Numbering is relative to the
transcription start site. See also Figure S2A.
(B) The effect of OCT1 on the expression of miR-451. Luciferase assay in 3T3 Oct1/ cells co-transfected with WT and mutant (S335A and S335D) OCT1
constructs and luciferase construct containing different putative OCT1 binding sites. See also Figure S2B. Mean ± SD.
(C–E) Glucose deprivation decreases the recruitment of OCT1 to the promoter of miR-451. ChIP analysis in low glucose conditions in miR-451 promoter regions
(C) was validated by qRT-PCR of OCT1 (D) and RNA Pol II (E). *p < 0.05, **p < 0.01. Mean ± SD.decreased (Figure 1C). The gradual decrease of pri-miR-451 in
cells switched to low glucose (Figure S1A) was closely mirrored
by mature miR-451, suggesting transcriptional rather than
post-transcriptional regulation (Figures S1B–S1D). This effect
was specific for miR-451, as levels of other microRNAs were
not significantly altered in low glucose (Figure S1E). Interest-
ingly, the introduction of exogenous LKB1 into HeLa cells, in
which the expression of pri-miR-451 is comparable to GBM
cells (Figure S1F), resulted in rescuing glucose-sensitive
response in pri-miR-451 expression concomitant with high
glucose-induced phosphorylation of AMPKa and OCT1 (Fig-
ure S1G). These results indicated that the expression of miR-
451 is inherently linked to glucose levels and that its expression
is most likely controlled transcriptionally.
The OCT1 Transcription Factor Drives the Expression of
miR-451
MiR-451 is encoded in a single intergenic locus at Ch.17 q11.2.
We screened 10 kb upstream of the miR-451 locus for putative
transcription factor binding sites using Tfsitescan (Farre´ et al.,
2003). In addition to previously described binding sites for
GATA-1 and AP-1 (Cheng et al., 2013; Dore et al., 2008), we iden-
tified several potential binding sites for OCT1 (Figures 2A and904 Cell Reports 11, 902–909, May 12, 2015 ª2015 The AuthorsS2A), a transcription factor in which genetic knockout promotes
adaptation to low glucose (Shakya et al., 2009). We thus hypoth-
esized that OCT1 regulates transcription of miR-451 based on
glucose availability. Series of reporter constructs with OCT1
binding sites was engineered (Figure 2A), and co-expression of
the clone 3 (C3) and clone 4 (C4) fragments (or both, clone 5
[C5]) with exogenous OCT1 led to significant induction of tran-
scriptional activity in 3T3 Oct1/ cells (Figure 2B), while the
C1 and/or C2 constructs had no effect. Phosphorylation of
OCT1 at S335 blocks its activity by preventing DNA binding
(Kang et al., 2011). OCT1 S335A and S335D phospho-site mu-
tantswere tested, and transcriptional activity of the constitutively
active S335A mutant was similar to WT, while that of the inactive
S335D mutant was negligible (Figures 2B and S2B). This indi-
cates that the predicted OCT1 binding sites in the miR-451 pro-
moter are functional.
ChIP assays were used to determine whether endogenous
OCT1 was recruited to the miR-451 gene promoter in a
glucose-dependent manner. Soluble chromatin from GBM U87
cells was isolated after culturing for 18 hr in low or high glucose
and then immunoprecipitated with an OCT1 antibody. There was
minor enrichment of OCT1 in the C1 and C2 regions irrespec-
tively of glucose regimen. In contrast, OCT1 was enriched
Figure 3. OCT1 Plays Critical Roles in miR-
451 Expression
(A and B) qRT-PCR analysis of pri-miR-451
expression upon OCT1 knockdown (A) and in
Oct1-deficient cells (B). See also Figures S2C and
S2D. *p < 0.05, **p < 0.01. Mean ± SD.
(C) qRT-PCR analysis of pri-miR-451 expression
upon OCT1 overexpression. See also Figure S2E.
*p < 0.05, **p < 0.01. Mean ± SD.
(D) qRT-PCR analysis of pri-miR-451 expression in
3T3Oct1/ cells transfected with WT and mutant
OCT1 vectors and cultured in high and low
glucose. See also Figures S2F and S2G. *p < 0.05,
**p < 0.01. Mean ± SD.
(E) The predominant nuclear localization of OCT1
in GBM cells is independent of glucose levels.
Immunoblotting of cytoplasmic (c) and nuclear (n)
cellular fractions of GBM cells cultured in high and
low glucose.
(F) OCT1 is phosphorylated at S335 in a glucose-
dependent manner in GBM cells. Immunoblotting
of GBM cells cultured in high and low glucose.
(G) OCT1 is phosphorylated at S335 in glucose-
dependent manner in mouse fibroblasts; phos-
phorylation of AMPK by low glucose conditions is
not impaired in Oct1/ cells. Immunoblotting of
3T3 cells cultured in high and low glucose.
(H) Knockdown of AMPK a1, a2, and a1/a2 in-
creases the expression of miR-451 in low glucose
environment. Immunoblotting of GBM cells
cultured in low glucose (upper). qRT-PCR analysis
of pri-miR-451 expression upon AMPK knock-
down (lower). See also Figure S2I. *p < 0.05, **p <
0.01. Mean ± SD.several-fold at the C3 and C4 regions in high glucose, while, in
low glucose, this enrichment was significantly reduced (Figures
2C and 2D). RNA Polymerase II recruitment to the miR-451 pro-
moter mirrored OCT1 recruitment (Figure 2E).
OCT1 Activity Inversely Correlates with AMPK
Activation
Knockdown studies were performed to further confirm the role of
OCT1 in miR-451expression. OCT1 siRNA transfection reduced
pri-miR-451 levels by 2-fold in GBM cells in high glucose (Fig-
ure 3A). MouseOct1/ fibroblasts cultured in high glucose were
characterized by remarkably low levels of pri-miR-451 when
compared with WT (Figures 3B and S1F). When OCT1 was tran-
siently overexpressed in GBM cells, levels of pri-miR-451 were
induced 4-fold (Figure 3C). Levels of mature miR-451 in
OCT1-depleted or overexpressing cells mirrored those of
the primary transcript (Figures S2C–S2E). When either WT orCell Reports 11, 902–9the constitutively active S335A mutant
OCT1 was transiently reintroduced into
Oct1/ mouse fibroblasts, miR-451
was significantly induced, while the intro-
duction of the OCT1 S335D mutant
construct had no effect. Interestingly,
only in cells with reintroduced WT OCT1
was the expression of miR-451 glucose
dependent, suggesting the potentialimportance of the S335 residue in this context (Figures 3D,
S2F, and S2G).
These results proved glucose-dependent binding of OCT1 to
the promoter region of the miR-451, indicating that high glucose
led to OCT1 transcriptional activation of miR-451. They also
showed the role of S335 phosphorylation in the activity of
OCT1. OCT1 in GBM cells is predominantly nuclear (75%–
90%) irrespective of glucose levels, suggesting that subcellular
distribution is not responsible for OCT1 regulation (Figure 3E).
The phosphorylation of S335 was significantly increased in
low glucose in two GBM cell lines (Figure 3F) and in WT, but
not in Oct1/ mouse fibroblasts, as expected (Figure 3G).
Also as expected, in all experiments, the phosphorylation of
AMPKa at T172 was significantly increased in low glucose (Fig-
ures 3F and 3G). Additionally, low miR-451 in Oct1/ mouse
fibroblasts correlated with higher levels of CAB39 protein, result-
ing in higher levels of LKB1 complex and moderately, but09, May 12, 2015 ª2015 The Authors 905
Figure 4. Role of AMPK in Phosphorylation
of OCT1 and Transcription of miR-451
(A) Phosphorylation of OCT1 at S335 is impaired in
AMPKb1/2-deficient GBM cells. Immunoblotting
of AMPKb1/2-deficient GBM cells cultured in high
and low glucose.
(B) qRT-PCR analysis of pri-miR-451 expres-
sion. See also Figure S3A. *p < 0.05, **p < 0.01.
Mean ± SD.
(C and D) AMPK directly phosphorylates OCT1 at
S335. Kinase assays were performed with AMPK
complex immunoprecipitated from U251 cells
expressing Flag-AMPK in low glucose conditions
(C), or recombinant, active AMPK complex con-
taining AMPKa1, b1, and g1 (D), and GST-OCT1
peptide fragment containing S335 or S335A. See
also Figures S3D–S3F.
(E) A proposed miR-451/AMPK regulatory loop in
a fluctuating glucose microenvironment.significantly, stronger activation of AMPK in low glucose condi-
tions (Figure S2H).
Based on this and on the fact that S335 in OCT1 has the high-
est score of all predicted AMPK phosphorylation sites (Xue et al.,
2006), we hypothesized that AMPK may be the kinase involved,
thereby providing a direct link between AMPK and transcription
of miR-451. Transient silencing of AMPK a1 and a2 subunits,
both separately and in combination using siRNA, led to induction
of miR-451 expression in low glucose, and silencing of both sub-
units led to a moderate additive effect, suggesting a partially
redundant function of the two subunits (Figure 3H). We did not
observe induction of miR-451 upon AMPK a1/2 knockdown in
high glucose, which suggested that only low glucose-activated
AMPK can suppress the OCT1/miR-451 axis (Figure S2I). These
findings thus showed that OCT1 phosphorylation is glucose
dependent and correlates with AMPK activity, suggesting that
AMPK may be responsible for the inactivating phosphorylation
of OCT1.
AMPK Directly Phosphorylates OCT1, Thus Inhibiting
Transcription of miR-451
We used AMPK b1/2 double-deficient T98 GBM cells (Liu et al.,
2014a; Liu et al., 2014b), which when exposed to low glucose
cannot fully activate AMPK (measured by the level of AMPK
a1/2 phosphorylation at T172; Figure 4A). We found that in these
cells the phosphorylation of OCT1 at S335 was unaltered in low
glucose, in sharp contrast to cells with fully functional AMPK
(Figures 3F, 3G, and 4A). Likewise, the expression of pri-miR-
451 was only partially suppressed in AMPK b1/2/ cells, while
strong suppression occurred in cells with a functional AMPK
pathway in low glucose (Figures 1A, 4B, and S3A). These results906 Cell Reports 11, 902–909, May 12, 2015 ª2015 The Authorsdemonstrated that expression of miR-
451 inversely correlates with activated
AMPK.
Inhibition of AMPK activity by the small
molecule inhibitor Compound C (Liu
et al., 2014a) resulted in the reduction of
OCT1 S335 phosphorylation (Figure S3B)
with a concurrent increase in miR-451levels, regardless of glucose status. This suggests that AMPK
activity (confirmed by phosphorylation of its direct target ACC),
rather than glucose availability, is the major mechanism of
miR-451 suppression (Figure S3C). To determine the role of
AMPK in phosphorylation of OCT1 at S335, we used two
in vitro kinase assays. First, the AMPK complex was immunopre-
cipitated from low glucose-cultured GBM cells overexpressing
Flag-tagged AMPKb1. Under low glucose, both AMPKa subunits
underwent phosphorylation, demonstrating the functionality
of the immunoprecipitated complex (Figures S3D–S3F). Co-
incubation of this AMPK complex with the GST-tagged peptide
encompassing the S355 OCT1 phosphorylation site resulted in
phosphorylation of the WT but not of the S335A mutant site (Fig-
ure 4C). Then the purified recombinant active AMPK complex
(SignalChem) was co-incubated with GST-tagged OCT1 pep-
tide, leading to the same result (Figure 4D). This demonstrates
that AMPK is sufficient in phosphorylating OCT1 at S335, thus
establishing AMPK as the kinase responsible in shutting off
OCT1-mediated transcription of miR-451 in response to glucose
availability.
We have previously shown that overexpression of miR-451
stimulated cell growth in high glucose (Godlewski et al.,
2010c). As shown in this study, in high glucose, OCT1 remains
unphosphorylated (Figure 3F), which prompted us to test
whether the presence and phosphorylation status of OCT1 af-
fects cell growth. We used AMPK-defective GBM cells and an
OCT1 overexpression strategy (Figure S4A) and found that over-
expression of WT and phosphor-deficient S335Amutant, but not
phosphomimetic S335Dmutant, increased cell proliferation (Fig-
ure S4B). This correlated with the levels of pri-miR-451 in these
cells (Figure S4C). This led us to ask whether the expression of
miR-451 in glioblastoma cells affects their growth in insuffi-
cient glucose. We used a time-dependent glucose depletion
model (see Figure 1B) and found that cells with dysfunctional
AMPK activation bymiR-451 overexpression were characterized
by faster growth rate as long as glucose remained sufficient
(Figure S4D). An in vivo flank xenograft study demonstrated
moderately, but significantly, enhanced growth of miR-451 over-
expressing cells (Figure S4E). To test the relevance of the
described model to patient-derived samples, we used a large
collection of primary glioblastoma neurospheres (Bronisz et al.,
2014) for miR-451 profiling (Figure S4F). We selected cells with
the strongest and the weakest expression of miR-451. As
demonstrated in Figures S4G and S4H, the dynamics of
AMPK/OCT1 phosphorylation upon glucose starvation were
dependent on basal levels of miR-451. This suggests that, in
patient-derived primary cells, low miR-451 levels allow faster
adaptation to low glucose stress by rapid activation of AMPK.
DISCUSSION
We show that there is a transcriptionally regulated microRNA-
based loop that links nutrient availability to activation of the
major energy sensor of the cell, AMPK. We demonstrated that
(1) glucose-dependent fluctuations in the levels of miR-451 are
regulated transcriptionally, (2) that multiple binding sites for the
OCT1 are present upstream of miR-451, (3) that binding of
OCT1 to these binding sites promotes transcription of miR-451
and that such binding is mediated by the phosphorylation of
OCT1 at S335, and (4) that AMPK kinase complex directly phos-
phorylates OCT1 at S335 in glucose-dependent manner. These
results thus show that the AMPK complex/OCT1/miR-451/
LKB-1 complex loop provides a nutrient-dependent regulatory
mechanism to allow the cell to adapt to changing microenviron-
mental conditions.
Previously, we reported that the expression of miR-451 is
regulated by glucose availability in GBM cells: miR-451 levels
were high in a glucose-rich environment and were low in glucose
depletion. This changed the respective phenotypic behaviors of
the cell from proliferative to migratory (Godlewski et al., 2010a,
2010c). We and others have shown that miR-451 is a potent
inhibitor of the AMPK signaling pathway by operating at multiple
levels. It directly targets CAB39—a co-activator of the AMPK
upstream kinase (Zeqiraj et al., 2009), LKB1, and 14-3-3z—a
functional inhibitor of AMPK-phosphorylated Raptor (Gwinn
et al., 2008). MiR-451 also diminishes the motility and migratory
behavior of GBM cells. These observations led us to postulate
the existence of an AMPK/miR-451 reciprocal negative feed-
back loop, mediated by glucose availability. The findings of
this paper demonstrate the existence and the mechanism
responsible for this loop.
The levels of pri-miR-451 are inherently linked to glucose
levels. Regardless of the glucose regimen used (withdrawal,
gradual depletion, and surge replenishment), the levels of
primary transcript are linked to glucose status. The glucose-
deprivation triggered downregulation of miR-451 seems to be
transcriptional (not dependent on processing), as the drop in
the level of mature miR-451 was always accompanied with a
drop in pri-miR-451. The effect is dynamically regulated and fullyreversible, as shown by experiments with glucose fluctuation
(Figures 1 and S1).
The analysis of region upstream to themiR-451 locus revealed
multiple putative binding sites for OCT1—a widely expressed
transcription factor (Kang et al., 2009). Oct1-deficient cells are
resistant to glucose deprivation due to reduction of glucose
metabolism (Shakya et al., 2009). We have demonstrated dy-
namic and glucose-dependent binding of OCT1 to its predicted
binding sites 6–8 kb upstream of the miR-451 locus, followed by
the recruitment of RNA polymerase II. The binding was S335
dependent, as only WT and constitutively active S335A mutant
OCT1 were capable of binding and inducing transcriptional
activity, showing that the phosphorylation at S335 is crucial for
OCT1 activity (Figures 2, S2A, and S2B). The abundance of
pri-miR-451 depends on the level of OCT1 protein and reintro-
duction of WT, and constitutively active S335A mutant OCT1
into Oct1-deficient cells rescued miR-451expression. Oct1
knockout mice are embryonically lethal due to faulty erythropoi-
esis (Wang et al., 2004). The latter is of interest, as miR-451 is
known as a crucial factor driving erythrocyte maturation in verte-
brates (Rasmussen and O’Carroll, 2011). Thus, the exceptionally
low levels of miR-451 observed in Oct1-deficient cells (Figures
3B and 3D) provide a plausible explanation for this in vivo pheno-
type. OCT1 becomes inactive in low glucose, suggesting that
AMPK may be responsible for its phosphorylation. AMPK
knockdown in low glucose resulted in de-repression of miR-
451 expression, while it had no effect in high glucose (Figures
3 and S2C–S2I). Our results suggest that the AMPK kinase com-
plex phosphorylates OCT1 in low glucose. In AMPK-deficient
cells, OCT1 remained largely dephosphorylated in low glucose,
resulting in the expression of miR-451. However, partial reduc-
tion of miR-451 in low glucose occurred, most likely due to
incomplete AMPK knockdown. We demonstrated by in vitro
kinase assays that AMPK is directly responsible for OCT1 phos-
phorylation and that an AMPK inhibitor prevented OCT1 shut
down in low glucose (Figures 4 and S3).
OCT1 is dynamically phosphorylated following the exposure
of cells to oxidative and genotoxic stress (Kang et al., 2009),
which are also known to activate AMPK (Sanli et al., 2013).
OCT1 phosphorylated at S335 lacks the ability to bind DNA
(Kang et al., 2009). Intriguingly, it was shown that phosphoryla-
tion of OCT1 at S335 during M-phase by Nek6 kinase results in
its exclusion frommitotic chromatin in LKB/AMPK signaling defi-
cient HeLa cells (Kang et al., 2011). MiR-451 is potent inhibitor of
AMPK signaling (Godlewski et al., 2010a), and AMPK-defective
cells are characterized by low phospho-OCT1 levels (Figure 4A).
On the other hand, miR-451 does not affect M-phase in GBM
cells (Godlewski et al., 2010c). Thus, the evidence for dynamic
phosphorylation of OCT1 upon stress and during cell cycle
exists; additionally, cell type and kinase availability may modify
the phosphorylation of OCT1. It remains to be investigated
whether phospho-OCT1 is in fact a mitotic marker in GBM cells
in the context of glucose availability.
In GBM cells, high glucose leads to miR-451 activity, the shut-
off of AMPK function, and cell proliferation. Conversely, in low
glucose AMPK activation occurs, turning on energy-conserving
and migratory behavior. Both the energy-conserving metabolic
shift and resource-seeking behavioral change require GBM cellCell Reports 11, 902–909, May 12, 2015 ª2015 The Authors 907
to shut down miR-451, while forced expression of miR-451 dur-
ing stress leads to cytotoxicity (Godlewski et al., 2010c). The
downregulation of miR-451 helps GBM cells to escape from
metabolically stressful events/locations. MiR-451 thus provides
example of a molecule that is not deregulated in GBM, but is
instead finely regulated by promoting or suppressing GBM cell
phenotypes based on microenvironmental contexts.
Because AMPK can impede cell growth, it was historically
perceived as a bona fide tumor suppressor. However, recently,
a number of studies have emerged that lead to the opposite
conclusion, namely that AMPK enables cancer cell survival
capabilities under stress (Jeon and Hay, 2012). The AMPK com-
plex endows cancer cells with the ability to survive the stressors,
including energy and growth factor deficiency and genomic
damage (Sanli et al., 2013). It provides a potent regulatory mech-
anism by which cancer cells temporarily halt growth onmicroen-
vironmental and therapy-inflicted challenges. Recent studies on
the role of AMPK demonstrate increased activity of AMPK in
malignant tissue compared with non-malignant tissue in vivo
and in cancer cells in vitro (Li et al., 2012; Park et al., 2009). Acti-
vation of AMPK by oncogenic events was demonstrated in
rodent models of brain tumors (Jang et al., 2011; Rı´os et al.,
2013). Active AMPK was detected in human GBM, and AMPK
inhibition, either by small molecule inhibitors or shRNA knock-
down, resulted in decreased growth of GBM xenografts (Liu
et al., 2014b; Rı´os et al., 2013). Thus, AMPK can be perceived
as contextual oncogene enabling cancer cells with behavioral
and biochemical flexibility.
In GBMs and other solid tumors, glucose metabolism is
elevated; yet rapid tumor growth can cause localized nutrient
deprivation. Thus, a potent and rapid response to glucose
deficiency could be beneficial to cell survival. Here we were
able to demonstrate that primary GBM cells with low levels of
miR-451 are capable of rapid and dynamic activation of AMPK
in response to glucose deprivation, which may lead to enhanced
cell survival in the presence of a stressor. Upon sensing dwin-
dling glucose availability, the AMPK complex becomes active
and, by direct phosphorylation of OCT1 at S335, prevents its
DNA binding/activity, resulting in rapidly declining levels of
miR-451 (Figure 4E). This, in addition to execution of energy-
saving and less glucose-dependent metabolic shift, allows
effective implementation of promigratory behavior of the cells
seeking for more favorable environment (Godlewski et al.,
2010c). Our and other researchers’ evidence (recently reviewed
by Vartanian et al., 2014) strongly suggests that the concept of
GBM cell plasticity at the metabolic level should be added to
the multifaceted landscape of this deadly disease.
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